Analysis shows the 340B program improves health care service access for eligible patients, highlighting collaboration with manufacturers.
The 340B Drug Pricing Program is a federal program that covered entities may use to extend the benefits of health care services to eligible patients. The program is an essential partnership between pharmaceutical manufacturers and covered entities. The benefits of the 340B Program include improved health for patients receiving services at these eligible locations.
No takes yet. Share an insight, caveat, or question.
Ransom et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: